文献速递脑血管病

安全简易新型急性缺血性卒中治疗的MCID

Minimal Clinically Important Difference for Safe and Simple Novel Acute Ischemic Stroke Therapies.
PubMed 文献 · Stroke · 2017-09-20

该研究对美国学术卒中神经科医生进行结构化网络调查,采用基数1000而非100的框架以减轻锚定偏倚。结果显示,在考虑锚定和中心性偏倚后,专家推导的安全急性缺血性卒中治疗的MCID为1.1%至1.5%,与指南撰写和临床实践中的实际医生行为一致。

要点

  • 专家调查得出的MCID受锚定和中心性偏倚影响。
  • 采用基数1000框架后,MCID中位数为1.3%(IQR 0.8%至>2%)。
  • 修正后的MCID为1.1%至1.5%,可指导临床试验设计。

核心结论

  • 卒中专家对MCID调查的应答受锚定和中心性偏倚影响。
  • 当调查设计考虑这些偏倚时,专家推导的安全急性缺血性卒中治疗的MCID为1.1%至1.5%。
  • 该修正后的MCID值与指南撰写和临床实践中的实际医生行为一致。

研究设计与样本

  • 对美国学术卒中神经科医生进行横断面结构化网络调查。
  • 共333名学术卒中神经科医生受邀,收到122份应答。
  • 调查采用基数1000而非100的患者框架以减轻锚定偏倚。

主要发现

  • 应答者中女性占23%,72.8%有≥6年执业经验,>70%的执业时间中神经血管病占一半以上。
  • 应答者-非应答者及抵抗连续体测试表明应答者代表整个专家群体。
  • 应答者报告的MCID中位数为1.3%(四分位距0.8%至>2%)。

关键数值与推荐

  • 专家推导的安全急性缺血性卒中治疗的MCID为1.1%至1.5%。
  • MCID定义为3个月功能独立患者比例绝对增加的最小临床重要差值。

临床怎么用

  • 修正后的MCID值可指导临床试验设计。
  • 该MCID值可指导基金资助和监管机构决策。

局限性

  • 调查仅纳入美国学术卒中神经科医生,可能限制普适性。
  • 应答率为122/333,虽经测试代表全专家群体,仍存在无应答偏倚可能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Determining the minimal clinically important difference (MCID) is essential for evaluating novel therapies. For acute ischemic stroke, expert surveys have yielded MCIDs that are substantially higher than the MCIDs observed in actual expert behavior in guideline writing and clinical practice, potentially because of anchoring bias. METHODS: We administered a structured, internet-based survey to a cross-section of academic stroke neurologists in the United States. Survey responses assessed demographic and clinical experience, and expert judgment of the MCID of the absolute increase needed in the proportion of patients achieving functional independence at 3 months to consider a novel, safe neuroprotective agent as clinically worthwhile. To mitigate anchoring bias, the survey response framework used a base 1000 rather than base 100 patient framework. RESULTS: Survey responses were received from 122 of 333 academic stroke neurologists, there were 23% women, 72.8% had ≥6 years of practice experience, and neurovascular disease accounted for more than half of practice time in >70%. Responder-nonresponder and continuum of resistance tests indicated that responders were representative of the full expert population. Among respondents, the median MCID was 1.3% (interquartile range, 0.8% to >2%). CONCLUSIONS: Stroke expert responses to MCID surveys are affected by anchoring and centrality bias. When survey design takes these into account, the expert-derived MCID for a safe acute ischemic stroke treatment is 1.1% to 1.5%, in accord with actual physician behavior in guideline writing and clinical practice. This revised MCID value can guide clinical trial design and grant-funding and regulatory agency decisions.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Cranston JS, Kaplan BD, Saver JL, et al. Minimal Clinically Important Difference for Safe and Simple Novel Acute Ischemic Stroke Therapies. Stroke. 2017. PMID: 28931621. doi:10.1161/STROKEAHA.117.017496

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。